Nonalcoholic fatty liver disease (NAFLD), including its more severe manifestation,
nonalcoholic steatohepatitis (NASH), has a global prevalence of 20–25% and is a major …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

There is considerable potential for integrating transarterial chemoembolization (TACE),
programmed death-(ligand) 1 (PD-[L] 1) inhibitors, and molecular targeted treatments (MTT) …

Although advances in spatial transcriptomics (ST) enlarge to unveil spatial landscape of
tissues, it remains challenging to delineate pathology-relevant and cellular localizations …

Importance The combination of immune checkpoint inhibitors with antiangiogenic agents
has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC) …

Comprehensive molecular analyses of metastatic hepatocellular carcinoma (HCC) are
lacking. Here, we generate multi-omic profiling of 257 primary and 176 metastatic regions …

Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Hepatocellular carcinoma (HCC) takes the predominant malignancy of hepatocytes with
bleak outcomes owing to high heterogeneity among patients. Personalized treatments …

Introduction The aim of this retrospective proof-of-concept study was to compare different
second-line treatments for patients with hepatocellular carcinoma and progressive disease …